Myasthenia gravis

Common Name(s)

Myasthenia gravis

Myasthenia gravis (MG) is an autoimmune disease that impacts an affected individual’s control of the skeletal muscles. The condition is typically seen in women below the age of 40, and in men above the age of 60. However, there are cases where MG has developed in individuals of all ages.

Symptoms of this condition may include muscle weakness, drooping eyelids, double vision, difficulty swallowing or eating, trouble talking, being unable to fully control facial expressions, fatigue, and difficulty breathing. The muscle weakness appears to increase after the individual is active, but then improves after rest.

Acetylcholine is a chemical that is normally present in the nervous system and is important for passing messages from the brain to the skeletal muscles. In individuals with MG, the body produces antibodies (proteins that are used to detect harmful agents in the body) which mistakenly attack certain sites that are responsible for receiving the acetylcholine messages. As a result, the symptoms of MG occur since the nervous system cannot communicate properly with the muscles. This response is an example of an autoimmune disease, where the body mistakenly begins attacking itself.

Removal of the thymus gland (an organ that is part of the immune system), blood plasma exchanges (where harmful antibodies are removed), and the use of certain types of medications are all current forms of treatment for MG. Other ways to manage the symptoms may include avoiding stressful situations and getting plenty of rest.

Although there is no cure for MG at this time, there are many treatment options available. Doctors seek help from various therapists and community services to provide support and care for families. Talk with a doctor or specialist if you or someone in your family has been diagnosed with Myasthenia gravis to discuss the most current treatment options.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myasthenia gravis" for support, advocacy or research.

Logo
Muscular Dystrophy Association

MDA is the nonprofit health agency dedicated to curing muscular dystrophy, ALS and related diseases by funding worldwide research. The Association also provides comprehensive health care and support services, advocacy and education.

Last Updated: 15 Jul 2015

View Details
Myasthenia Gravis Foundation of America, Inc.

MGFA is committed to finding a cure for myasthenia gravis and closely related disorders, improving treatment options, and providing information and support to people with myasthenia gravis through research, education, community programs, and advocacy.

Last Updated: 29 Apr 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myasthenia gravis" for support, advocacy or research.

Logo
Muscular Dystrophy Association

MDA is the nonprofit health agency dedicated to curing muscular dystrophy, ALS and related diseases by funding worldwide research. The Association also provides comprehensive health care and support services, advocacy and education.

http://www.mdausa.org

Last Updated: 15 Jul 2015

View Details
Myasthenia Gravis Foundation of America, Inc.

MGFA is committed to finding a cure for myasthenia gravis and closely related disorders, improving treatment options, and providing information and support to people with myasthenia gravis through research, education, community programs, and advocacy.

http://www.myasthenia.org

Last Updated: 29 Apr 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Myasthenia gravis" returned 970 free, full-text research articles on human participants. First 3 results:

Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report.
 

Author(s): Yu-Hsiu Chen, Feng-Cheng Liu, Chang-Hung Hsu, Chih-Feng Chian

Journal: Medicine (Baltimore). 2017 Jul;96(27):e7350.

 

Nivolumab (Nivo) is an immune checkpoint inhibitor that has been used to treat advanced melanoma, nonsmall cell lung carcinoma, and renal cell carcinoma since 2015. Nivo is associated with several side effects, including hepatitis, pneumonitis, acute renal failure, endocrine disorder, ...

Last Updated: 6 Jul 2017

Go To URL
TNFAIP3 gene rs7749323 polymorphism is associated with late onset myasthenia gravis.
 

Author(s): Hong-Wei Yang, Yanchen Xie, Yuan Zhao, Liang Sun, Xiaoquan Zhu, Shuhui Wang, Yong-Qiang Zhang, Ping Lei, Yunxiao Meng

Journal: Medicine (Baltimore). 2017 May;96(20):e6798.

 

In this study, we intended to genotype 2 single nucleotide polymorphisms (SNPs) of tumor necrosis factor α-induced protein 3 (TNFAIP3) genes and explore an association of TNFAIP3 genetic polymorphism with the patients of myasthenia gravis (MG) at clinical level. In brief, 215 of ...

Last Updated: 17 May 2017

Go To URL
Clinical predictors for the prognosis of myasthenia gravis.
 

Author(s): Lili Wang, Yun Zhang, Maolin He

Journal:

 

Clinical predictors for myasthenia gravis relapse and ocular myasthenia gravis secondary generalization during the first two years after disease onset remain incompletely identified. This study attempts to investigate the clinical predictors for the prognosis of Myasthenia Gravis.

Last Updated: 19 Apr 2017

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Myasthenia gravis" returned 72 free, full-text review articles on human participants. First 3 results:

Minimal change disease in a patient with myasthenia gravis: A case report.
 

Author(s): Jun-Li Tsai, Shang-Feng Tsai

Journal: Medicine (Baltimore). 2016 Sep;95(39):e5008.

 

Myasthenia gravis superimposed with proteinuria is a very rare disorder with only 39 cases reported so far. Of these cases, the most commonly associated disorder is minimal change disease. Myasthenia gravis and minimal change disease are both related to the dysfunction of T lymphocytes ...

Last Updated: 30 Sep 2016

Go To URL
[Myasthenia gravis - optimal treatment and accurate diagnosis].
 

Author(s): Nils Erik Gilhus, Emilia Kerty, Sissel Løseth, Åse Mygland, Chantal Tallaksen

Journal:

 

Around 700 people in Norway have myasthenia gravis, an autoimmune disease that affects neuromuscular transmission and results in fluctuating weakness in some muscles as its sole symptom. The diagnosis is based on typical symptoms and findings, detection of antibodies and neurophysiological ...

Last Updated: 6 Jul 2016

Go To URL
International consensus guidance for management of myasthenia gravis: Executive summary.
 

Author(s): Donald B Sanders, Gil I Wolfe, Michael Benatar, Amelia Evoli, Nils E Gilhus, Isabel Illa, Nancy Kuntz, Janice M Massey, Arthur Melms, Hiroyuki Murai, Michael Nicolle, Jacqueline Palace, David P Richman, Jan Verschuuren, Pushpa Narayanaswami

Journal: Neurology. 2016 Jul;87(4):419-25.

 

To develop formal consensus-based guidance for the management of myasthenia gravis (MG).

Last Updated: 27 Jul 2016

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Myasthenia Gravis and Psyche
 

Status: Recruiting

Condition Summary: Myasthenia Gravis

 

Last Updated: 29 Jun 2017

Go to URL

Last Updated: 5 Jul 2017

Go to URL
Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
 

Status: Recruiting

Condition Summary: Myasthenia Gravis, Generalized

 

Last Updated: 10 Apr 2017

Go to URL